Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation.

Antoun A, Vekaria D, Salama RA, Pratt G, Jobson S, Cook M, Briggs D, Moss P.

Br J Haematol. 2012 Dec;159(5):589-98. doi: 10.1111/bjh.12072. Epub 2012 Oct 1.

PMID:
23025544
2.

A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding.

Zuo J, Willcox CR, Mohammed F, Davey M, Hunter S, Khan K, Antoun A, Katakia P, Croudace J, Inman C, Parry H, Briggs D, Malladi R, Willcox BE, Moss P.

Sci Signal. 2017 May 30;10(481). pii: eaai8904. doi: 10.1126/scisignal.aai8904.

PMID:
28559451
3.

NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies.

Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Kanda Y, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan Marrow Donor Program.

Haematologica. 2009 Oct;94(10):1427-34. doi: 10.3324/haematol.2009.008318.

4.

Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.

Gagne K, Busson M, Bignon JD, Balère-Appert ML, Loiseau P, Dormoy A, Dubois V, Perrier P, Jollet I, Bois M, Masson D, Moine A, Absi L, Blaise D, Charron D, Raffoux C; ARS2000 FRM and FGM group.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1366-75. doi: 10.1016/j.bbmt.2009.06.015.

5.

Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.

Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, Holowiecki J, Holowiecka-Goral A, Markiewicz M, Kopera M, Karolczyk A, Kyrcz-Krzemien S, Kusnierczyk P.

Eur J Haematol. 2009 Oct;83(4):343-56. doi: 10.1111/j.1600-0609.2009.01280.x. Epub 2009 Jun 2.

PMID:
19500138
6.

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.

Björklund AT, Schaffer M, Fauriat C, Ringdén O, Remberger M, Hammarstedt C, Barrett AJ, Ljungman P, Ljunggren HG, Malmberg KJ.

Blood. 2010 Apr 1;115(13):2686-94. doi: 10.1182/blood-2009-07-229740. Epub 2010 Jan 22.

7.

NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.

van der Straaten HM, Paquay MM, Tilanus MG, van Geloven N, Verdonck LF, Huisman C.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1231-6. doi: 10.1016/j.bbmt.2010.12.709. Epub 2011 Jan 6.

8.

Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.

Sobecks RM, Askar M, Thomas D, Rybicki L, Kalaycio M, Dean R, Avery R, Mossad S, Copelan E, Bolwell BJ.

Exp Clin Transplant. 2011 Feb;9(1):7-13.

11.

Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.

Kanga U, Mourya M, Seth T, George J, Sood P, Sharma R, Saxena A, Mehra NK.

Transplant Proc. 2012 May;44(4):919-21. doi: 10.1016/j.transproceed.2012.03.036.

PMID:
22564585
12.

P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.

Lee KH, Park SS, Kim I, Kim JH, Ra EK, Yoon SS, Hong YC, Park S, Kim BK.

Haematologica. 2007 May;92(5):651-7.

13.
14.

NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation.

Haas P, Loiseau P, Tamouza R, Cayuela JM, Moins-Teisserenc H, Busson M, Henry G, Falk CS, Charron D, Socié G, Toubert A, Dulphy N.

Blood. 2011 Jan 20;117(3):1021-9. doi: 10.1182/blood-2010-02-269381. Epub 2010 Nov 2.

15.

Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors.

Bosch-Vizcaya A, Pérez-García A, Brunet S, Solano C, Buño I, Guillem V, Martínez-Laperche C, Sanz G, Barrenetxea C, Martínez C, Tuset E, Lloveras N, Coll R, Guardia R, González Y, Roncero JM, Bustins A, Gardella S, Fernández C, Buch J, Gallardo D; GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (GETH).

Biol Blood Marrow Transplant. 2012 Jan;18(1):100-5. doi: 10.1016/j.bbmt.2011.05.021. Epub 2011 Jun 12.

17.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT).

Haematologica. 2009 Apr;94(4):542-9. doi: 10.3324/haematol.2008.000927. Epub 2009 Mar 10.

18.

Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.

Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K.

Am J Hematol. 2008 Sep;83(9):721-7. doi: 10.1002/ajh.21247.

19.

Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations.

Antoun A, Jobson S, Cook M, O'Callaghan CA, Moss P, Briggs DC.

Hum Immunol. 2010 Jun;71(6):610-20. doi: 10.1016/j.humimm.2010.02.018. Epub 2010 Mar 15.

PMID:
20219610
20.

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Pérez-García A, De la Cámara R, Román-Gómez J, Jiménez-Velasco A, Encuentra M, Nieto JB, de la Rubia J, Urbano-Ispizúa A, Brunet S, Iriondo A, González M, Serrano D, Espigado I, Solano C, Ribera JM, Pujal JM, Hoyos M, Gallardo D; GVHD/Immunotherapy Committee of the Spanish Group of Hematopoietic Stem Cell Transplantation.

Blood. 2007 Jul 1;110(1):461-7. Epub 2007 Mar 23.

Supplemental Content

Support Center